Immunization

Childhood Hepatitis A Vaccine Deemed Cost-Effective

Published in Medical Letter on the CDC and FDA, July 16th, 2000

Researchers say that since childhood hepatitis A vaccine costs less than $50,000 per years of live saved (YOLS) it is cost-effective in the United States, particularly in areas with high rates of hepatitis A virus (HAV).

To determine the cost-effectiveness of hepatitis A vaccine among U.S. children, A.S. Meyerhoff and colleagues from Capitol Outcomes Research, Inc., in Alexandria, Virginia, and the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia, designed a model to assess the lifetime HAV incidence of "a single birth cohort with and without vaccination."

They presented the study results at the 10th International Symposium on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry